3,772 reports of this reaction
1.6% of all AMBRISENTAN reports
#15 most reported adverse reaction
NASAL CONGESTION is the #15 most commonly reported adverse reaction for AMBRISENTAN, manufactured by Gilead Sciences, Inc.. There are 3,772 FDA adverse event reports linking AMBRISENTAN to NASAL CONGESTION. This represents approximately 1.6% of all 240,584 adverse event reports for this drug.
Patients taking AMBRISENTAN who experience nasal congestion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASAL CONGESTION is a less commonly reported adverse event for AMBRISENTAN, but still significant enough to appear in the safety profile.
In addition to nasal congestion, the following adverse reactions have been reported for AMBRISENTAN:
The following drugs have also been linked to nasal congestion in FDA adverse event reports:
NASAL CONGESTION has been reported as an adverse event in 3,772 FDA reports for AMBRISENTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASAL CONGESTION accounts for approximately 1.6% of all adverse event reports for AMBRISENTAN, making it a notable side effect.
If you experience nasal congestion while taking AMBRISENTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.